In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a price ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has earned a consensus rating of “Buy” from the fifteen ratings ...

Axsome Therapeutics (AXSM) stock gains as company settles patent dispute with Hikma (HKMPF) over sleep therapy Sunosi. Read ...

Meeting to be held in New York on March 6 hosted by Piper Sandler.Discover the Best Stocks and Maximize Your Portfolio: See what stocks are ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective hoisted by stock analysts at Robert W. Baird from ...

Axsome Therapeutics (NASDAQ:AXSM) said on Monday that in the FDA meeting minutes, the agency has supported a supplemental NDA ...

Biopharmaceutical firm Axsome Therapeutics (NASDAQ:AXSM) reported mixed fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 18. The company achieved substantial revenue growth, with sales ...

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Axsome's stock has risen 47% since my August recommendation, driven by FDA approvals and revenue growth. See why I maintain ...

Axsome Therapeutics, a biopharmaceutical company targeting central nervous system (CNS) disorders, develops novel therapies for depression, narcolepsy, and other CNS conditions. Its current ...